Short-Term Outcome of Infliximab Therapy in Pediatric Crohn’s Disease: A Single-Center Experience
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Studies on the efficacy of infliximab (IFX) in a large population of pediatric patients with Crohn’s disease (CD) are limited, and prognostic factors are not well-known. The aim of this study was to evaluate outcomes of IFX in pediatric patients with CD and to identify factors associated with poor prognosis.Methods: We retrospectively analyzed medical data of 594 pediatric patients with CD between 1987 and 2013 in a tertiary center. Of these, 156 children treated with IFX were enrolled and were followed up for at least a year with intact data. Outcomes of induction and maintenance, classified as failure or clinical response, were evaluated onthe tenth and 54th week of IFX therapy.Results: We treated 156 pediatric patients with CD with IFX, and the median duration of IFX therapy was 47 months. For IFX induction therapy, 134 (85.9%) patients experienced clinical response on the 10th week. Among the 134 patients who showed response to induction, 111 (82.8%) patients maintained the clinical response on the 54th week. In multivariate analysis, low hematocrit (p=0.046) at the time of IFX initiation was associated with the failure of IFX induction. For IFX maintenance therapy, longer duration from the initial diagnosis to IFX therapy (p=0.017) was asso-ciated with maintenance failure on the 54th week.Conclusion: We have shown the acceptable outcomes of IFX in a large cohort of pediatric CD patients in Korea. Hematocrit and early introduction of IFX may be prognostic factors for the outcomes of IFX.
Abstract
Purpose: Studies on the efficacy of infliximab (IFX) in a large population of pediatric patients with Crohn’s disease (CD) are limited, and prognostic factors are not well-known. The aim of this study was to evaluate outcomes of IFX in pediatric patients with CD and to identify factors associated with poor prognosis.Methods: We retrospectively analyzed medical data of 594 pediatric patients with CD between 1987 and 2013 in a tertiary center. Of these, 156 children treated with IFX were enrolled and were followed up for at least a year with intact data. Outcomes of induction and maintenance, classified as failure or clinical response, were evaluated onthe tenth and 54th week of IFX therapy.Results: We treated 156 pediatric patients with CD with IFX, and the median duration of IFX therapy was 47 months. For IFX induction therapy, 134 (85.9%) patients experienced clinical response on the 10th week. Among the 134 patients who showed response to induction, 111 (82.8%) patients maintained the clinical response on the 54th week. In multivariate analysis, low hematocrit (p=0.046) at the time of IFX initiation was associated with the failure of IFX induction. For IFX maintenance therapy, longer duration from the initial diagnosis to IFX therapy (p=0.017) was asso-ciated with maintenance failure on the 54th week.Conclusion: We have shown the acceptable outcomes of IFX in a large cohort of pediatric CD patients in Korea. Hematocrit and early introduction of IFX may be prognostic factors for the outcomes of IFX.
참고문헌 (30)
- Molodecky NA, "Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review", Gastroenterology, 142, pp.46~54 (2012)
- Adamiak T, "Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin:a population-based epidemiological study", Inflamm Bowel Dis, 19, pp.1218~1223 (2013)
- Kim BJ, "Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: a single-center experience", Dig Dis Sci, 55, pp.1989~1995 (2010)
- Grossi V, "The safety of treatment options for pediatric Crohn's disease", Expert Opin Drug Saf, 15, pp.1383~1390 (2016)
- Ruemmele FM, "Consensus guidelines of ECCO", ESPGHAN on the medical management of pediatric Crohn's disease, 2014, pp.8, 1179~1207
- 박재준, "Second Korean guidelines for the management of Crohn’s disease", Intestinal research, 15(1), pp.38~67 (2017), 대한장연구학회
- Hosoi K, "Treatment with infliximab for pediatric Crohn's disease: nationwide survey of Japan", J Gastroenterol Hepatol, 32, pp.114~119 (2017)
- Lee YM, "Infliximab "top-down" strategy is superior to "step-up" in maintaining long-term remission in the treatment of pediatric Crohn disease", J Pediatr Gastroenterol Nutr, 60, pp.737~743 (2015)
- Luo Y, "Efficacy of infliximab in treatment of pediatric Crohn's disease in China", Zhonghua Er Ke Za Zhi, 52, pp.688~692 (2014)
- Hyams J, "Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children", Gastroenterology, 132, pp.863~873 (2007)
- Walters TD, "Increased effectiveness of early therapy with anti-tumor necrosis factor-αvs an immunomodulator in children with Crohn's disease", Gastroenterology, 146, pp.383~391 (2014)
- Jennifer C. deBruyn, "Long-term Outcomes of Infliximab Use for Pediatric Crohn Disease", Journal of Pediatric Gastroenterology and Nutrition, 66(2), pp.268~273 (2018), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Hyams JS, "Long-term outcome of maintenance infliximab therapy in children with Crohn's disease", Inflamm Bowel Dis, 15, pp.816~822 (2009)
- Vahabnezhad E, "A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease", Inflamm Bowel Dis, 20, pp.606~613 (2014)
- IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, "Inflammatory bowel disease in children and adolescents:recommendations for diagnosis--the Porto criteria", J Pediatr Gastroenterol Nutr, 41, pp.1~7 (2005)
- Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease:the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)
- Best WR, "Development of a Crohn's disease activity index. National cooperative Crohn's disease study", Gastroenterology, 70, pp.439~444 (1976)
- Hyams JS, "Development and validation of a pediatric Crohn's disease activity index", J Pediatr Gastroenterol Nutr, 12, pp.439~447 (1991)
- Hyams J, "Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience", J Pediatr Gastroenterol Nutr, 41, pp.416~421 (2005)
- Grossi V, "Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn's disease", Clin Gastroenterol Hepatol, 13, pp.1748~1756 (2015)
- Church PC, "Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease", Inflamm Bowel Dis, 20, pp.1177~1186 (2014)
- Crombé V, "Long-term outcome of treatment with infliximab in pediatric-onset Crohn’s disease: a population-based study", Inflamm Bowel Dis, 17, pp.2144~2152 (2011)
- Ruffolo C, "Infliximab, azathioprine, or combination therapy for Crohn's disease", N Engl J Med, 363, pp.1086~1087 (2010)
- Koutroubakis IE, "Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease", Clin Gastroenterol Hepatol, 13, pp.1760~1766 (2015)
- Rieder F, "Hemoglobin and hematocrit levels in the prediction of complicated Crohn's disease behavior--a cohort study", PLoS One, 9, pp.e104706~ (2014)
- Koutroubakis IE, "The influence of anti-tumor necrosis factor agents on hemoglobin levels of patients with inflammatory bowel disease", Inflamm Bowel Dis, 21, pp.1587~1593 (2015)
- Bergamaschi G, "Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment", Haematologica, 95, pp.199~205 (2010)
- Nahon S, "Diagnostic delay is associated with a greater risk of early surgery in a French cohort of Crohn's disease patients", Dig Dis Sci, 61, pp.3278~3284 (2016)
- Ma C, "Anti-TNF therapy within 2years of Crohn's disease diagnosis improves patient outcomes: a retrospective cohort study", Inflamm Bowel Dis, 22, pp.870~879 (2016)
- Oh EH, "Early anti-TNF", immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors, 2017, pp.12, e0177479~